Strategic Pharma Alliances Protillion's Prot-MaP on-chip antibody discovery combined with a lab-in-the-loop AI-driven design platform makes it a compelling partner for large pharma pursuing multi-target discovery and accelerated biologics programs. The Merck collaboration example demonstrates a clear path to joint development opportunities and milestone-driven engagements.

Platform Licensing The high-throughput discovery platform can be licensed or deployed via CRO partnerships, enabling biotechs and pharma companies to access cutting-edge protein display technology without building in-house capabilities. This positions Protillion for scalable, recurring revenue through licensing deals and service collaborations.

AI Powered Services The integrated AI and wet-lab feedback loop differentiates Protillion from traditional discovery services, enabling end-to-end discovery programs, sponsored research, and potential co-development arrangements with shared risk and reward.

Growth Readiness A new Chief Scientific Officer and strong venture backing signal Protillion’s capacity to scale programs, expand commercial operations, and engage in larger, longer-term research engagements with pharma and biotech customers.

Regional Strategy Based on the West Coast with access to vibrant biotech clusters, Protillion should target regional biotechs, CROs, and academic partnerships for pilot studies and early collaborations, building a local pipeline and faster deal cycles.